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ABSTRACT: Pharmaceuticals and industrial chemicals, both in
the environment and in research settings, commonly interact with
aquatic vertebrates. Due to their short life-cycles and the traits that
can be generalized to other organisms, fish and amphibians are
attractive models for the evaluation of toxicity caused by
endocrine disrupting chemicals (EDCs) and adverse drug
reactions. EDCs, such as pharmaceuticals or plasticizers, alter
the normal function of the endocrine system and pose a significant
hazard to human health and the environment. The selection of
suitable animal models for toxicity testing is often reliant on high
sequence identity between the human proteins and their animal
orthologs. Herein, we compare in silico the ligand-binding sites of
28 human “side-effect” targets to their corresponding orthologs in
Danio rerio, Pimephales promelas, Takifugu rubripes, Xenopus laevis, and Xenopus tropicalis, as well as subpockets involved in
protein interactions with specific chemicals. We found that the ligand-binding pockets had much higher conservation than the full
proteins, while the peroxisome proliferator-activated receptor γ and corticotropin-releasing factor receptor 1 were notable
exceptions. Furthermore, we demonstrated that the conservation of subpockets may vary dramatically. Finally, we identified the
aquatic model(s) with the highest binding site similarity, compared to the corresponding human toxicity target.
■ INTRODUCTION
Aquatic vertebrates are targeted by pharmaceutical and
industrial chemicals, both intentionally and unintentionally, in
a variety of research and environmental contexts. In the wild,
these animals are exposed to the pharmaceuticals and industrial
chemicals present in the surface waters. In research settings,
aquatic vertebrates may be used to evaluate novel chemicals for
toxicity, including the early identification of adverse drug
reaction (ADR) or endocrine disruption (ED) potential of
pharmaceutical candidates and industrial chemicals.
Lower order vertebrates, such as amphibians and fish, are
being increasingly viewed as a replacement for rodent models.
They are convenient and cost-effective model organisms due to
their short life-cycles and the presence of traits that can be
generalized to other organisms.1 Species that are commonly
used for toxicological evaluations include Danio rerio (zebra-
fish), Pimephales promelas (fathead minnow), Takifugu rubripes
(Japanese pufferfish), Xenopus laevis (African clawed frog), and
Xenopus tropicalis (Western clawed frog).1−4 Specifically, D.
rerio has been widely used to study ADRs that include
reproductive toxicity, cardiotoxicity, hepatotoxicity, and neuro-
toxicity,5 as well as the evaluation of potential endocrine
disrupting chemicals (EDCs; reviewed in ref 1). P. promelas has
been used to predict the aquatic toxicity of environmental
chemicals,2 and T. rubripes has been used to evaluate EDCs.6,7
Amphibians are known to be good models for studying EDCs
that interact with thyroid hormone receptors8 and X. laevis has
been used to study ADRs related to membrane transporters.9
Toxicity, for chemicals with low concentrations in the target
organisms, is most frequently caused by their specificity to
particular proteins in the organism. Comparing the protein
sequences and structures of human toxicity targets to their
orthologs in aquatic species can assist in the identification of
the most similar ortholog.
For the reliable prediction of pharmaceutical or environ-
mental toxicity, robust animal models are required whose
proteins are highly similar to the orthologous human ADR and
toxicity targets. Additionally, in the wild, these species are more
vulnerable than others to pharmaceuticals present in the
environment that have been specifically designed for high-
affinity interactions with the designated proteins.10
Typically in toxicity studies, one rodent model and one
nonrodent model are employed.11 However, depending on the
target and the class of chemicals in question, some animal
models may be more relevant than others. The ever-increasing
number of species with fully sequenced genomes has begun to
allow for druggable genome and proteome comparisons.
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Recently, the genomes of eight relevant toxicological species
were compared to the human genome.12 Target similarity has
been assessed at the level of protein sequence, with the degree
of conservation of specific drug targets in humans and model
organisms evaluated by performing sequence-by-sequence
alignments,10 and limited studies have been conducted on the
domain conservation for the androgen receptor (AR) and
estrogen receptor α (ERα).13
Nevertheless, the levels of conservation between orthologous
sequences usually vary throughout the sequence (Figure 1).
Thus, it is important to focus on the similarity of sections of the
sequence that are most relevant to chemical interactions. The
conservation of residues directly involved in ligand binding is a
more relevant parameter for evaluation of aquatic species
models than full sequence similarity. Interspecies variations in
the amino-acid composition of the binding-pocket can
sometimes have dramatic effects on the utility of species in
pharmacological assays. For example, in the serotonin 6
receptor (5-HT6R), two residues in the ligand-binding pocket
were found to significantly change the pharmacology of the
mouse 5-HT6R (resulting in a systematic one log unit shift of
the 5-HT6R ligands), compared to the human and rat 5-
HT6R,
15,16 making the mouse model an unfavorable choice for
testing 5-HT6R-targeting pharmaceuticals, while the rat 5-
HT6R binding pocket is identical to humans. Similarly, two
(out of 13) minor amino-acid substitutions (Thr to Ala and Ala
to Val) in the binding pocket of the rat and mouse histamine
H3 receptors (H3R), compared to the human H3R, lead to a
systematic compound potency measurement error and limits
both of their utilities in H3-related studies.
17
Because orthologous proteins in different species typically
bind the same or similar endogenous ligands,8 the conservation
of the binding pockets far exceeds the full length sequence
conservation. They are also likely to bind the same exogenous
chemicals. The aim of this research was to identify the aquatic
organisms (from the set of D. rerio, P. promelas, T. rubripes, X.
laevis, and X. tropicalis) that share the highest binding pocket
similarity with humans in each of the 28 best-characterized
toxicity targets. X-ray crystal structures were used to identify
the amino-acid residues constituting the ligand-binding pockets,
which were extrapolated to the aquatic orthologs. Sequence
similarity and identity were calculated for the ligand-binding
sites, and the most similar orthologs to the 28 human toxicity
targets were identified.
■ MATERIALS AND METHODS
Selection of Human EDC and ADR Targets. An initial
set of 85 unique human proteins that have been previously
characterized as side-effect and toxicity targets were compiled
from the 73 protein assays listed in the Novartis in vitro safety
panels (Table S1, Supporting Information), 11 targets from the
VirtualToxLab,18,19 and the Constitutive Androstane Receptor
(CAR; NR1I3). All 85 proteins were used for sequence
analyses. For binding pocket similarity analyses, the 85 targets
were matched against the Pocketome encyclopedia (http://
pocketome.org),20 a collated set of annotated, binding pocket
structure ensembles from the Protein Data Bank (PDB).21 At
the time of this study, 28 out of the 85 targets had Pocketome
entries for their ligand-binding pockets available (Table S1,
Supporting Information) that contained at least one cocrystal-
lized ligand making it possible to precisely identify the binding
site residues. These 28 targets were used for binding site
similarity and identity comparisons.
Identification of Orthologs of Human EDC and ADR
Targets in the Aquatic Species. The complete proteomes of
D. rerio, Mus musculus (mouse), P. promelas, Rattus norvegicus
(rat), T. rubripes, X. laevis, and X. tropicalis were downloaded in
FASTA format from the UniProt Knowledgebase.22 The M.
musculus and R. norvegicus results have been included in all
Supporting Information for comparison purposes. For each of
the files, BLAST search index was generated using the
bioinformatics module of the Internal Coordinate Mechanics
(ICM) software version 3.7-3a (Molsoft L.L.C., La Jolla,
CA).23,24 A BLAST search25 was performed to identify
orthologs of the 85 human proteins in the corresponding
aquatic species. One hit per target per species was retained
using the following prioritization rules: (i) manually annotated
orthologs of the toxicity and side-effect targets were retained
with the highest priority; (ii) for automatically annotated
analogues, orthologs with the same gene name as the human
protein and the highest probability score to the human protein
were kept; (iii) if only sequence fragments were available, the
longest fragment was retained.
Sequence Alignment and Analysis. Pairwise alignments
were constructed between the full sequence of human protein
and the corresponding orthologs, and pairwise sequence scores
were calculated with the Needleman and Wunsch algorithm26
modified for the zero end-gap penalties (the ZEGA
algorithm27) as implemented in the ICM program. We used
gap opening and gap extension penalties of 2.4 and 0.15,
respectively. Sequence identity was represented by the number
of identical residues over the total number of aligned residues.
Sequence similarity was calculated using the GONNET residue
substitution comparison matrix.28
Binding Site Definition and Classification Using
Ligand Contact Strength Fingerprints. For each ligand in
the pocketome entry and each non-hydrogen atom in the
protein, distance-dependent contact strengths were calculated
Figure 1. Variations in sequence conservation across the sequence of the AR for D. rerio, P. promelas, T. rubripes, X. laevis, and X. tropicalis compared
to the human AR (binding site residues highlighted in cyan). All sequences were window averaged across 25 residues. Abbreviations: AF1/2,
activation function 1/2; DBD, DNA binding domain; LBD, ligand binding domain.14
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using the parameters developed in context of GPCR Dock 2010
evaluation.29,30 The per-atom contact strengths were aggre-
gated into per-residue contact strength values by taking the sum
over all non-hydrogen atoms in the residue side-chain. Only
residue side-chains were included in the calculation because,
except for proline, ligand contacts with backbone atoms may
not be affected by residue substitutions between species. If a
ligand was cocrystallized in multiple structures, the vectors of
per-residue contact strengths were averaged. To reduce noise
and binding site definition artifacts associated with increased
conformational variability of individual residues, the contact
strength vector components were multiplied by a factor ranging
from 0 to 1 and inversely proportional to the observed
conformational variability of the corresponding residue in the
Pocketome ensemble.
Each unique ligand Li was characterized by a vector FPi of
per-residue numbers ranging from 0 (no contact) to 32
(extensive close contact with Phe168 in the adenosine A2A
receptor (A2AR); Table S1, Supporting Information). Normal-
ized fingerprint distance between ligands Li and Lj was
calculated as D = 1 − (ΣMin(FPi,FPj))/(Σ(FPi + FPj)/(2))
where Min(FPi,FPj) and (FPi+FPj)/2 are vectors of element-
wise minima and element-wise averages between vectors FPi
and FPj, respectively.
30 When defined that way, ligand
fingerprint distances range from 0 (for identical fingerprints)
to 1 (for nonoverlapping fingerprints). Ligand interaction
Figure 2. Sequence similarity (percentage and color) and sequence identity (number of identical residues/number of aligned residues is shown in
parentheses) for the 28 toxicity target proteins of (a) the full sequence and (b) the ligand-contact residues conserved for 80% of the cocrystallized
ligands. White spaces indicate that no ortholog was identified (often due to an incomplete proteome).
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fingerprints were clustered at the distance cutoff of D = 0.35 to
identify classes of ligand occupying distinct areas in the binding
site. The cutoff of 0.35 was found to be the optimal trade-off
between the excessive number of clusters and the unwanted
aggregation of substantially different ligand chemotypes in
multiple targets. This cutoff indicates that the ligands will be
classified as belonging to different clusters if their fingerprints
vary by one-third (or more) of the contacts.
Next, clusters of unique crystallographic ligands were ordered
by their size, starting with the most populated one and ending
with singletons (i.e., clusters containing only a single ligand).
Top clusters containing 80% of the ligands were combined to
define the set of residues interacting with the majority of the
ligands. The remaining 20% were disregarded in the pocket
definition to ensure that it is not affected by occasional or
spurious contacts.
Binding Pocket Sequence Identity and Similarity
Calculations. For each subpocket in the binding site, as
determined by ligand contact strength fingerprint clustering, a
subalignment was extracted by projecting the full sequence
alignment between human and ortholog sequences onto the
corresponding residue selection. Binding pocket/subpocket
identity and similarity were calculated from these subalign-
ments using the same parameters as the full sequence
alignments. The same was done for the set of residues forming
the interaction site(s) for at least 80% of the ligands, as
described above, and thus represent the aggregation of the
consistently populated regions of the pocket. The comparison
of complete pockets (including interaction fingerprints of all
crystallographic ligands) is available in Supporting Information.
■ RESULTS
Orthologs of Human EDC and ADR Targets in Aquatic
Vertebrates. Five fish and amphibians frequently used in
toxicological evaluations were used in this study: D. rerio, P.
promelas, T. rubripes, X. laevis, and X. tropicalis. In their
proteomes, we identified the orthologs of the known human
side-effect and environmental target proteins. In some cases,
orthologs could not be found: 89% of the toxicity targets were
identified in D. rerio, 20% in P. promelas, 84% in T. rubripes,
51% in X. laevis, and 85% in X. tropicalis (Table S1, Supporting
Information). This may be explained by the fact that only the
genomes of D. rerio,31,32 T. rubripes,33 and X. tropicalis34 have
been fully sequenced, while the remaining two genomes (P.
promelas and X. laevis), and thus proteomes, are incomplete.
Additionally, in some cases, only protein fragments of the
toxicity target orthologs have been identified. The sequences of
the human and orthologous toxicity proteins were aligned, and
the full sequence similarity was calculated (Figure 2a, Table S1,
Supporting Information).
Full Sequence Similarity between Human EDC/ADR
Targets and Their Orthologs in Aquatic Vertebrates. The
relevance of a model organism for prediction of toxicity in
humans has previously been evaluated using the amino acid
conservation across entire protein sequences, e.g., ref. 10. In the
present study, the majority of the human toxicity targets
displayed 60−70% sequence similarity with their aquatic
vertebrate orthologs (Figure 2a). The average full sequence
similarity between the human proteins and the aquatic
orthologs was 69% for D. rerio, 63% for P. promelas, 70% for
T. rubripes, 71% for X. laevis, and 72% for X. tropicalis (Figure
S1, Supporting Information). In some cases, the overall
sequence similarity was relatively high. For example, X.
tropicalis had the highest full sequence similarity for the
androgen receptor (AR, 88%). However, the protein sequence
for X. tropicalis was only a fragment of the full sequence that
lacked the N-terminal domain of the protein compared to the
other species, giving artificially higher sequence similarity. The
corticotropin-releasing factor receptor 1 (CRF1R) is highly
conserved in four species (∼85% sequence similarity). The
interspecies variations in full sequence similarity were more
informative for the estrogen receptors α and β (ERα and ERβ,
respectively), and the glucocorticoid receptor (GR), where the
full sequences were similar in length. X. laevis and X. tropicalis
shared higher conservation of these receptors with human (9−
24% higher sequence similarity) than with D. rerio, P. promelas,
and T. rubripes. The impact of the variability of the sequence
length on the full sequence similarity demonstrates the
difficulties with using the full protein sequence (or longest
available sequence) in these calculations.
Ligand-Binding Pocket Similarity between Human
EDC/ADR Targets and Their Orthologs in Aquatic
Vertebrates. As expected, the ligand-binding pockets of the
orthologous proteins generally shared higher sequence
conservation with the human toxicity targets than the full
protein sequences (Figure 2b). For example, the ligand-binding
site of human AR shared ∼98% sequence similarity with all five
species, whereas the full sequence similarity was only 47−88%.
Likewise, the binding sites of ERα, ERβ, and GR are 92−100%
conserved in all five aquatic species, while the highest full
sequence conservation observed in X. laevis and X. tropicalis did
not exceed 70−76%. The relative ranking of species by the full
sequence similarity to humans often varies from that by binding
pocket similarity. For example, on the basis of full sequence
similarity, one would choose X. laevis or X. tropicalis as the most
relevant model for testing ERα-targeting chemicals; however,
our pocket similarity analysis indicates that all five species are
almost equally good, with the fish species having a slight
advantage over the frogs. Similarly, despite being most similar
to human in terms of full β2 adrenergic receptor (β2AR)
sequence, X. tropicalis is probably the least accurate of the five
models for evaluation of β2AR ligand pharmacology, as it has as
many as 5 residue substitutions in the binding pocket (Figure
S3, Supporting Information).
Surprisingly, two targets had lower sequence conservation in
the binding site as compared to the full sequence. These were
the obesity- and stress-related targets, peroxisome proliferator-
activated receptor γ (PPARγ) and CRF1R. PPARγ displayed
lower binding-site similarity (56−85%) than full sequence
similarity (74−89%). CRF1R displayed higher sequence
similarity across the full protein sequence (∼85%) than in
the peptide-binding site in its extracellular domain (46−78%).
However, GPCRs often have a greater degree of sequence
variability in the extracellular domains; hence, the lower
sequence similarity in the peptide-binding site of CRF1R is
consistent with the nature of this receptor.
Ligand-Binding Pockets in ADR/EDC Targets: One
Size Does Not Fit All. On closer inspection of the ligand-
binding interactions in the X-ray crystal structures of the human
EDC and ADR targets, there were often noticeably different
residue interaction fingerprints for different ligand chemotypes.
In some cases, different chemotypes can bind to distinct ligand-
binding pockets or “sub-pockets” of the proteins.
This is exemplified by the identification of three different
subpockets of the adenosine A2A receptor (A2AR). Promisingly,
the three subpockets identified for A2AR (Figure 3a)
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correspond to an agonist-bound structure (Figure 3b), the
endogenous agonist-bound structure (Figure 3c), and the
antagonist-bound structures (Figure 3d), respectively. All
subpockets were fully conserved in X. laevis and X. tropicalis.
Additionally, significant variations in the conservation of
subpockets can be observed for the ortholog of β2AR in X.
tropicalis (Figure S3, Supporting Information), where subpock-
et 1 displays 75% conservation, yet subpocket 2 has only 48%
sequence similarity.
Because the likelihood of a chemical interacting with an
aquatic species ortholog of its target protein largely depends on
the conservation of specific interacting residues and not the
entire binding site, we sought to identify the individual
subpockets in each of the target pockets and to separately
evaluate their similarity to the corresponding subpockets in the
studied aquatic organisms. Subpockets were identified by the
clustering of contact-strength fingerprints (see Materials and
Methods).
GPCR Subpocket Sequence Conservation. GPCRs are a
superfamily of membrane bound proteins characterized by
seven transmembrane (TM) helices and many have been
implicated in ADRs, endocrine disruption, and reproductive
toxicity.35 The A2AR is implicated in a number of ADRs such as
palpitations and angina.18 ADRs for the β2 adrenergic receptor
(β2AR) include tremor, cardiac failure, and angina;
18 it has also
been implicated in ED in aquatic vertebrates.4,36 The serotonin
2B receptor (5-HT2BR) is linked to valvular heart disease;
37 the
histamine H1 receptor (H1R) is involved in sedation, and the
human M2 muscarinic acetylcholine receptor (M2R) is
associated with constipation.18 The dopamine D3 receptor
(D3R) is implicated in dyskinesia and Parkinsonism
18 and
shown to bind the known endocrine disruptor BPA.38 Two
class B GPCRs were also evaluated: CRF1R, which is implicated
in stress-related disorders,39,40 and the gastric inhibitory
polypeptide receptor (GIPR), which is implicated in diabetes
and obesity.41
Two subpockets were identified for β2AR (Figure S3,
Supporting Information), the classical orthosteric site (sub-
pocket 1) and the orthosteric site with some additional residues
from the less conserved TM1/TM2/TM7 region (subpocket
2). Generally, X. tropicalis displayed poor ligand-binding pocket
conservation to the human β2AR (75% and 48%, subpockets 1
and 2, respectively). Due to the scarcity of multiple crystal
structures for many GPCRs, subpockets were unable to be
explored for the 5-HT2BR, D3R H1R, κ opioid receptor (κOR),
and M2R; however, the binding pockets were generally well
conserved (69−100%; Figures 2b and S4, Supporting
Information).
At the time of this study, crystal structures were only
available for the extracellular domains of the GPCRs CRF1R
and GIPR, which contain the peptide-binding sites. These
peptide-binding sites were expected to have lower levels of
conservation because it is well established that the extracellular
domains of GPCRs have a large degree of sequence variability.
Only X. tropicalis had a moderately conserved ortholog for
GIPR (61%, Figure S4, Supporting Information), indicating
that alternate animal models should also be investigated. X.
laevis and X. tropicalis displayed higher ligand-binding pocket
similarity across both subpockets (60−78%, Figure S4,
Supporting Information). However, it is unlikely that peptides
in the environment would result in endocrine disruption via the
peptide-binding site of CRF1R and GIPR in either humans or
the fish and amphibians evaluated in this study, as potential ED
peptides are unlikely to be readily absorbed. Consequently, this
Figure 3. (a) Sequence similarity (percentage and color) and sequence identity (number of identical residues/number of aligned residues is shown
in parentheses) for the three A2AR subpockets (white spaces indicate that no ortholog was identified). A2AR crystal structures (gray ribbons), all
cocrystallized ligands (mesh), and subpocket (solid surface); (b) subpocket 1 (agonist-bound structures), (c) subpocket 2 (the endogenous agonist-
bound structure), and (d) subpocket 3 (antagonist-bound structures).
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technique should also be applied to the small molecule binding
site of GIPR when a structure becomes available and to the
recently released structure of CRF1R.
42
Nuclear Receptor Subpocket Conservation. Nuclear
receptors are a superfamily of proteins that regulate develop-
ment, growth, and homeostasis, and they are commonly
implicated in endocrine disruption. Some classic examples of
ED that occur via nuclear receptors include the weak agonistic
activity of the plasticizer bisphenol A (BPA) against the ERα;43
the feminization of fish by 17α-ethinylestradiol (EE2), a
synthetic estrogen in human contraceptives;44 and modulation
of PPARγ by EDCs, which is implicated in obesity.45
ERα subpockets were generally highly conserved across the
aquatic species (94−100%, Figure S5, Supporting Information),
with the exception of T. rubripes for subpocket 8, which is
bound to a large estradiol metal chelate ligand (88%). The
binding pocket of ERβ across the five species, compared to the
human ERβ, was generally highly conserved (92−100%, Figure
S4, Supporting Information). However, across all the
subpockets, T. rubripes was slightly less conserved (92−95%
vs. 98−100%). ERR1 has only been cocrystallized with two
unique ligands in two unique subpockets (Figure S4,
Supporting Information), with subpocket 2, cocrystallized
with a thiazolidinedione, having higher sequence conservation
(82−89% vs. 54−60%). The subpockets of the glucocorticoid
receptor (GCR) were generally well conserved with the human
receptor (91−98%, Figure S4, Supporting Information). The
binding sites of the progesterone receptor (PR) for X. laevis and
X. tropicalis shared slightly higher pocket conservation with the
human receptor (98−100%, Figure S4, Supporting Informa-
tion). The subpockets of the androgen receptor (AR) were
highly conserved (96−100%, Figure S6, Supporting Informa-
tion), and the subpockets of the thyroid hormone receptor β
(TRβ) were fully conserved (100%, Figure S4, Supporting
Information). Unlike TRβ, the thyroid hormone receptor α
(TRα) did not show full sequence conservation across all
species (86−100%; Figure S4, Supporting Information). All
subpockets across all species (except for P. promelas for which
no ortholog was identified) were fully conserved for the Liver X
Receptor (LXR; Figure S4, Supporting Information). While no
subpockets were identified for the mineralocorticoid receptor
(MCR; Figure S4, Supporting Information), X. tropicalis had
the lowest LBD similarity (81%). Of the five aquatic species, T.
rubripes consistently displayed higher homology to the human
Pregnane X receptor (PXR; 54−64%, Figure S7, Supporting
Information). Despite this, the overall pocket similarity was
relatively low (maximum 64%), indicating that PXR is not well
conserved in these aquatic vertebrates and that other animal
models with higher binding site conservation should also be
investigated. Similarly, low binding-pocket conservation was
observed for the Constitutive Androstane Receptor (CAR; 35−
43%; Figure S4, Supporting Information). In 15 out of the 16
subpockets, X. tropicalis had the highest ligand-binding pocket
sequence similarity to the human PPARγ (81−100%; Figure
S8, Supporting Information). Interestingly X. laevis, a close
relative of X. tropicalis, had significantly lower ligand-binding
pocket sequence similarity (50−80%).
Cytochrome P450 Subpocket Sequence Conserva-
tion. Cytochrome P450s (CYPs) are a superfamily of enzymes
that catalyze the oxidation of a diverse range of organic
compounds and are commonly involved in the metabolism of
xenobiotic compounds. CYPs typically have large and
conformationally flexible binding sites in order to accommodate
a wide range of chemically dissimilar compounds,46,47 which is
supported by the diverse array of subpockets identified. There
were closely related orthologs to the human CYP1A2, with D.
rerio having the highest pocket similarity (96%, Figure S4,
Supporting Information). Both D. rerio and P. promelas had
closely related orthologs of CYP3A4 across five out of six
subpockets (89−100%, Figure S9, Supporting Information). X.
laevis and X. tropicalis had the highest subpocket similarities for
CYP2C9 (60−78%); however, the ligand-binding pocket
conservation was moderate (Figure S4, Supporting Informa-
tion). Orthologs of CYP2D6 were only identified in X. laevis
and X. tropicalis, which displayed good conservation to the
human protein (Figure S4, Supporting Information).
Subpocket Sequence Conservation of Other En-
zymes. Monoamine oxidase A (MAO-A) is involved in the
catabolism of neurotransmitters and dietary amines; inhibition
can lead to neuroendocrine disruption,48 and it is implicated in
ADRs including psychosis and hypertensive crisis.49 ADRs
associated with cAMP-specific 3′,5′-cyclic phosphodiesterase
4D (PDE4D) include diarrhea and nausea,50 and due to its role
in the endocrine system, PDE4D may also be a target for
EDCs.51 The binding site of PDE4D was fully conserved across
the identified ortholog binding sites (100%, Figure S4,
Supporting Information). The subpockets for MAO-A,
however, displayed higher sequence similarity for D. rerio and
T. rubripes (95%, Figure S4, Supporting Information).
■ DISCUSSION
The present study performs a comparison of 28 human toxicity
targets to their orthologs in five aquatic species, with the goal of
identifying the aquatic organisms with the highest ligand-
binding pocket sequence similarity to the human toxicity target.
The comparison was performed not only at the level of full
protein sequences but also, more relevantly, at the level of the
ligand-binding sites. By using the X-ray crystal structures of
human toxicity targets, residue-level interaction fingerprints
were calculated for each unique cocrystallized ligand, and
binding pockets and spatially distinct subpockets were
identified, with each residue selection extrapolated onto the
orthologous proteins in the five aquatic vertebrates. In some
cases, the contact fingerprints could also separate the toxicity
target crystal structures based on the mode of action of the
cocrystallized ligands (such as A2AR; Figure 3), providing a
basis for understanding the subpocket sequence conservation.
We identified the aquatic vertebrate(s) that share the highest
sequence similarity for the ligand-binding pockets (Table 1),
compared to the human toxicity targets, as well as determined
the sequence similarity of the spatially distinct subpockets. X.
tropicalis had the largest number of orthologs that shared the
highest conservation with the human toxicity targets (out of the
five aquatic species), having the highest ligand-binding site
similarity for 21 out of the 28 toxicity targets, closely followed
by D. rerio (19), T. rubripes (19), and X. laevis (18). P. promelas
had the lowest number of highly conserved ligand-binding
pockets with only 7 ligand-binding sites with high similarity,
which can be partially attributed to an incomplete genome.
In this study, we demonstrated that the major difficulty faced
when using the full sequence similarity for the comparison of
toxicity target orthologs to human proteins is due to variations
in the length of the amino acid sequences. For example, while
X. tropicalis has the highest full sequence similarity for AR
(88%), the longest available sequence of the AR of X. tropicalis
was actually incomplete, lacking the N-terminal of the protein
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including the DNA binding domain (393 residues vs. >729
residues), thus giving artificially higher sequence similarity. This
also occurred for some of the aquatic orthologs of MCR,
PDE4D, PPARγ, PR, TRα, and TRβ. Additionally, we have
shown that high full sequence similarity does not always
correlate with high ligand-binding site conservation. For
example, the sequence similarity for the extracellular domains
of CRF1R for all species is high (∼85%), yet the peptide-
binding sites have lower conservation (46−78%). Generally, we
have demonstrated that the ligand-binding sites share higher
conservation between orthologs, compared to the full
sequences (Figure 2). Consequently, we also have shown that
the ligand-binding site similarity is the preferred method for the
identification of the most conserved orthologs, because it is
more informative than the full sequence similarity and it is not
influenced by variations in the length of the longest available
amino acid sequence of an ortholog. Additionally, if full
sequence similarity alone is to be considered, variations in the
length of the full (or longest available sequence) should also be
incorporated into these assessments.
There are a few caveats that need to be taken into
consideration when using orthologous sequence comparisons
to aid in the selection of animal models for the evaluation of
toxicity. First, the provided principles only suggest toxicity
target orthologs in aquatic species based on sequence similarity,
without attention to possible variations in the protein function
or the downstream pathways.10,52 This method unfortunately
does not provide any detail regarding the signaling pathways for
orthologous protein and will, of course, require a certain level
of understanding of the animal model. Binding pocket similarity
may be a necessary but not a sufficient condition for model
utility, as exemplified by the pair of human and rat ARs: a large-
scale study of interspecies variations in binding affinity of
chemicals17 identified this pair as having systematic one log unit
differences in potency of multiple diverse chemicals, despite the
fact that not only the binding pockets but also the entire ligand
binding domain of AR is strictly conserved between human and
rat. Second, our method is reliant on the availability of the
proteome of the organisms or, at the very least, the availability
of sequences of the orthologs of the toxicity targets. Third,
calculating ligand-binding site conservation requires X-ray
crystal structures of the human toxicity targets, preferably in a
complex with a diverse range of chemicals. Both of the
problems regarding the availability of the full proteomes and
crystal structures can be addressed in future studies, due to the
increasing availability of these data. Thus, this study could be
expanded to a wider range of toxicity targets and species,
including toxicity targets that lack crystal structures, by using
crystal structures of highly homologous proteins.
By calculating the amino acid similarity in the ligand-binding
pockets, we have successfully avoided the problem of full
sequence length variability in sequence similarity calculations,
to determine the aquatic orthologs with the most similar ligand-
binding pockets for 28 human toxicity targets. This method also
allows for the calculation of binding site similarity for
subpockets that are involved in the specific chemical−protein
interactions. We believe that this study will be a useful tool
when designing target-specific assays for the assessment of
ADRs and ED potential of chemicals.
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